The Novel Antitubulin Agent TR-764 Strongly Reduces Tumor Vasculature and Inhibits HIF-1α Activation

Tubulin binding agents (TBAs) are commonly used in cancer therapy as antimitotics. It has been described that TBAs, like combretastatin A-4 (CA-4), present also antivascular activity and among its derivatives we identified TR-764 as a new inhibitor of tubulin polymerization, based on the 2-(alkoxyca...

Descripción completa

Detalles Bibliográficos
Autores principales: Porcù, Elena, Persano, Luca, Ronca, Roberto, Mitola, Stefania, Bortolozzi, Roberta, Romagnoli, Romeo, Oliva, Paola, Basso, Giuseppe, Viola, Giampietro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904223/
https://www.ncbi.nlm.nih.gov/pubmed/27292568
http://dx.doi.org/10.1038/srep27886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4904223/
https://www.ncbi.nlm.nih.gov/pubmed/27292568
http://dx.doi.org/10.1038/srep27886

Ejemplares similares